Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02852655 |
Title | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma |
Recruitment | Completed |
Gender | both |
Phase | Phase 0 |
Variant Requirements | No |
Sponsors | Dana-Farber Cancer Institute |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |